P1/2, N=6, Terminated, Intellia Therapeutics | N=54 --> 6 | Trial completion date: Sep 2025 --> Aug 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Jul 2022; Pivoting to an allogeneic version of this program currently in preclinical development.
2 years ago
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A)
In addition, NTLA-5001 drug product displayed cytotoxic functionality when exposed to cell lines presenting the target WT1 peptide. The NTLA-5001 clinical-scale manufacturing process is a controlled and robust platform for the generation of minimally differentiated T cells with high rates of editing and transgene expression.
3 years ago
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule) • TRB (T Cell Receptor Beta Locus) • SELL (Selectin L)
This can be achieved with CRISPR/Cas9-mediated replacement of the endogenous TCR α and β chains, by knocking out the TRAC and TRBC genes and inserting the tgTCR into the TRAC locus. NTLA-5001 is being advanced into clinical development for AML immunotherapy. Given the expression of WT1 in many solid tumors, engineered WT1 TCR-T cells are being further explored in those indications.
4 years ago
Preclinical • IO biomarker
|
CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)